A 58-year-old man with type 2 diabetes on metformin has a HbA1c of 8.6%. He has an eGFR of 52 mL/min/1.73m², established atherosclerotic cardiovascular disease, and BMI 32 kg/m². Which agent should be added FIRST according to current ADA guidelines?

• A Sitagliptin
• B Glimepiride
• C Pioglitazone
• D Empagliflozin ✓

Explanation

Current ADA guidelines (2024) recommend an SGLT2 inhibitor as preferred add-on to metformin in patients with established ASCVD, given its proven cardiovascular mortality benefit (EMPA-REG OUTCOME trial). Empagliflozin is safe at eGFR ≥30 for cardiovascular benefit even when glycaemic effect diminishes. Sitagliptin and glimepiride are neutral regarding CV events; pioglitazone requires caution with fluid retention and heart failure risk.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.